ORTEX Pulse
One-sentence market alerts triggered by data threshold crossings across short interest, cost to borrow, options flow, analyst ratings, and institutional positioning.
ORTEX Pulse
Showing 1301–1350 of 19935.
ASTSASTS short sellers face critical squeeze risk as utilization hits 100%, with availability collapsing 75.6% in one week to just 2.6% — making new short positions nearly impossible to establish.4 Sept 2026SOLSSOLS short interest plunges 28% in one week to 5.9% of float, as cost to borrow stays negligible at 0.37%.4 Sept 2026ASSTASST utilization surges to 90.39%, highest since late August, as borrow availability plummets to 7.48%—a squeeze-ready setup for remaining short holders.4 Sept 2026XRPXRP short interest falls to 3.37% of float, down 43.8% in one week as shares borrowed drop to 203K.4 Sept 2026BLSHBLSH utilization hits 94.79%, down from 100% but still critically tight—shorts face severe squeeze pressure as availability barely exceeds 6%.4 Sept 2026TENBTENB short interest surges 49% in one week to 12.3% of float, highest since late August, as availability plummets 69% to 281%.4 Sept 2026LITELITE cost to borrow surges 104% in one week to 0.36%, signaling tighter short supply despite declining short interest at 10.1% of float.4 Sept 2026MOOMOO short sellers face maximum borrow squeeze as utilization hits 100%, availability plunges to 63%—lowest since late August.4 Sept 2026SOCSOC utilization hits 100%, maxed out for 52 weeks—availability plummets to 5.7%, up sharply week-over-week but still critically tight for short sellers trying to borrow shares.4 Sept 2026HYGHYG utilization hits 93.39%, near the 52-week high of 100%, as availability plummets to just 7.6% — making it increasingly difficult to borrow shares in the high-yield bond ETF.4 Sept 2026ONDSONDS short borrow completely frozen at 100% utilization, matching 52-week high, as 60.2% short interest remains among Nasdaq's most shorted names despite ongoing bear cover.4 Sept 2026HCMHCM cost to borrow doubles to 6.75% in two days, up 104% from last week as borrowing demand tightens on HUTCHMED (China) Limited, the AIM-listed pharma stock. Utilization hits 82%, highest in months.4 Sept 2026USOUSO cost to borrow soars to 8.51%, up 136% in one week amid intense short squeeze pressure.4 Sept 202623032303 cost to borrow surges to 1.55%, up 229% in one week amid tight semiconductor supply dynamics.4 Sept 2026LEULEU short interest utilization hits 100%, matching 52-week high—all available shares to borrow fully deployed as short positioning holds at 33% of float.4 Sept 2026AMDAMD cost to borrow surges 152% to 0.72%, highest level in a month as short positions hold steady.4 Sept 2026MFGMFG utilization hits 100%, matching 52-week high, as availability plummets 65% in one week to just 8%.4 Sept 2026SMFGSMFG short sellers face tightening availability as utilization hits 91.41%, near the 52-week high of 93.23%.4 Sept 2026TSMTSM cost to borrow surges to 0.40% — highest jump in a week, up 132% from Sept. 2 low of 0.01%.4 Sept 2026INGING cost to borrow surges 113% over one week to 0.58%, though remains at historically low levels. Short availability stands elevated at 401%, indicating ample shares available for borrowing relative to current short interest.4 Sept 2026BALYBALY short sellers face total squeeze potential—utilization maxed at 100% with availability near zero, cost to borrow surging 263% in one week.4 Sept 2026BHPBHP short sellers face tightening supply: utilization hits 91%, down from 100% but still critically high, with availability near lows at 6.5% of short interest.4 Sept 2026SOUNSOUN utilization hits 100%, the highest level on record, signaling an exhausted lending pool with zero availability for new short positions.4 Sept 2026TSLLTSLL utilization hits 100%, with availability plunging to 0.12% — nearly all shares to borrow are lent out. Cost to borrow surges 31% over one week to 7.74%, highest since late July.4 Sept 2026HYGHYG utilization hits 99.73%, highest since tracking began, as shares to borrow plummet to 2.2% availability.4 Sept 2026ORAORA Bernstein upgrades to Market Perform from Underperform; $112 price target maintained as stock trades at $104.19, down 0.5% today.4 Sept 202623032303 cost to borrow surges to 1.83%, up 368% in one week as demand for borrows accelerates despite ample availability.4 Sept 2026XRPXRP short interest plummets 81.5% in one week to 2.74% of float, lowest level in recent months.4 Sept 2026BALYBALY short sellers face maxed-out borrowing conditions. Utilization hit 100%, tied to its 52-week peak, while availability collapsed to 0.74%—near-zero shares remain available to borrow despite 1.08M shares short. Cost to borrow surged 263% in one week to 22.1%, signaling acute scarcity.4 Sept 2026BALYBALY cost to borrow jumps to 22.1%, up 263% in one week amid near-zero share availability.4 Sept 2026TENBTENB short interest surges 50% over one week to 12.3% of float, highest level in months as availability plummets 68%.4 Sept 2026CPBCPB put/call ratio surges to 0.927, highest in nearly a year—4.2 standard deviations above the 20-day mean of 0.685, signaling extreme options bullishness as stock drops 7% in one session.4 Sept 2026APHAPH put-call ratio hits 3.94, the highest level in 52 weeks, signaling extreme fear among options traders as the stock plunges 49% over the past month.4 Sept 2026LTGOLTGO short interest surges 41% in one week to 350,409 shares, up 12% in a single day, as cost to borrow climbs to 4.02%.3 Sept 2026FLNCFLNC Barclays downgrades to Underweight, slashes price target 37% to $10, citing execution risks on crowded FY27 backlog.3 Sept 2026NVSTNVST upgraded to Overweight by JP Morgan with $32 price target, up 10% from $29; stock at $27.39 near 1-month lows despite short interest surging 47% over past month to 7.4% of float.3 Sept 2026NVSTNVST short interest surges 21% over one week to 7.36% of float, highest level in recent months.3 Sept 2026AVGOAVGO Macquarie upgrade to Outperform with $490 price target announced today, marking shift from prior Neutral rating. Stock closed at $367.24, implying 33% upside to new PT; consensus target stands at $530.51. Multiple analyst moves today signal broad conviction across the Street.3 Sept 2026ZTOZTO JP Morgan downgrades to Neutral, slashes price target 24% to $22 from $29.3 Sept 2026RARERARE JP Morgan cuts target 55%, downgrades to Neutral as Wall Street reassesses rare-disease biotech outlook.3 Sept 2026ITRITR short interest jumps 13.6% in one day to 0.38% of float, though remains down 23% over the past week as bearish bets continue to unwind on the junior gold developer.3 Sept 2026AGXAGX Lake Street upgrade to Buy, $600 target after month-long selloff.3 Sept 2026MTAMTA short interest surged 554% over one week to 0.09% of float, though the stock gained 8.2% on Sept 2 and cost-to-borrow remains subdued at 0.93%. Availability stands elevated at 213%, easing short pressure despite the spike.3 Sept 2026CPRTCPRT upgrades to Overweight with $40 target, implying 24% upside from current levels.3 Sept 2026LEULEU short interest utilization hits 100%, capped at max 52-week level with zero shares available to borrow as of Sept 2, 2026.3 Sept 2026TDTD cost to borrow spikes 160% in one week to 0.45%, driven by tightening loanable share availability amid minimal short interest at 1.6% of float.3 Sept 2026RARERARE William Blair downgrades to Market Perform; analyst consensus remains Buy with $28.68 price target versus current $26.53.3 Sept 2026BLSHBLSH utilization hits 96.55%, near 52-week peak of 100%, as availability rises to 6.21% after dipping below 0.05% last month.3 Sept 2026CNHCNH upgraded to Outperform by Evercore ISI Group, target price raised to $18 from $12.50—44% upside from current $13.65 level.3 Sept 2026DEDE short interest climbs to 1.9% of float after earnings, lowest level in recent months, as Evercore ISI upgrades to Outperform with $813 price target—28.6% above prior $632 call.3 Sept 2026